Lynparza Side Effects on Liver Function Tests
Lynparza (olaparib) can cause hepatotoxicity including severe and potentially fatal drug-induced liver injury (DILI), requiring baseline liver function testing and ongoing monitoring throughout treatment. 1
Liver-Related Side Effects
Documented Hepatotoxicity
Lynparza causes hepatotoxicity through multiple mechanisms:
- Drug-induced liver injury (DILI) - including severe and potentially fatal cases 1
- Hepatocellular injury - characterized by elevated aminotransferases (ALT/AST) 2, 3
- Oxidative stress and mitochondrial dysfunction - leading to hepatocellular damage 4
- Immune-mediated liver injury - documented cases requiring corticosteroid treatment 3
Real-world data shows hepatobiliary adverse reactions occur with olaparib, with cases ranging from mild transaminase elevations to severe hepatocellular injury requiring drug discontinuation 5, 2.
Clinical Presentation
Patients may present with:
- Elevated ALT and AST (most common pattern)
- Jaundice and elevated bilirubin
- Abdominal discomfort
- Dark urine
- Liver synthetic dysfunction (in severe cases)
One documented case showed CTCAE Grade 4 hepatocellular injury that resolved with drug cessation but recurred upon rechallenge 2.
Monitoring Protocol
Baseline Assessment
Evaluate bilirubin and transaminases before starting Lynparza 1. The baseline panel should include:
- ALT
- AST
- Alkaline phosphatase (ALP)
- Total bilirubin (TBIL)
Ongoing Monitoring Schedule
Monitor liver tests at least monthly or before each treatment cycle 6. More specifically:
- Standard monitoring: Check ALT, AST, ALP, and TBIL before each cycle or monthly minimum 6
- Increased frequency: If abnormalities develop, monitor more frequently for liver test trends and clinical signs of hepatotoxicity 1
- Post-treatment: Continue monitoring for at least five half-lives after drug cessation (olaparib half-life is approximately 15 hours, so monitor for at least 3-4 days post-discontinuation) 6
Critical Thresholds for Action
Withhold Lynparza if:
- ALT ≥3× ULN AND total bilirubin ≥2× ULN (with ALP ≤2× ULN) in patients with near-normal baseline 6
- For patients with baseline ALT 1.5-3× ULN: use 4× ULN threshold
- For patients with baseline ALT 3-5× ULN: use 6× ULN threshold 6
Discontinue Lynparza permanently if:
- DILI is confirmed after comprehensive evaluation 1
- Liver injury fails to resolve or worsens despite drug cessation 6
Management Algorithm
When Liver Tests Elevate:
Immediate action: Withhold olaparib if meeting threshold criteria above 1
Comprehensive evaluation to exclude alternative causes:
Pattern recognition: Calculate R value = (ALT/ALT ULN)/(ALP/ALP ULN)
- R ≥5: hepatocellular pattern (typical for olaparib)
- R ≤2: cholestatic pattern
- R 2-5: mixed pattern 6
Additional testing if needed:
- Direct bilirubin (DBIL)
- GGT and 5'-nucleotidase (to clarify ALP source)
- INR and albumin (assess synthetic function) 6
Monitor weekly until resolution to Grade 1 or baseline 1
Consider liver biopsy if liver tests fail to improve or worsen despite drug cessation and other testing is unremarkable 6
Critical Clinical Pearls
Do not rechallenge with olaparib if DILI is confirmed - one case report documented recurrent Grade 4 hepatotoxicity upon rechallenge 2. However, switching to an alternative PARP inhibitor (niraparib) was successful, indicating no cross-reactive hepatotoxicity between different PARP inhibitors 2.
Immune-mediated cases may require corticosteroids - at least one case required prednisone taper for resolution 3.
Older patients (≥65 years) do not show increased hepatotoxicity risk compared to younger patients, though they have higher neutropenia risk with olaparib monotherapy 8.
Avoid grapefruit and Seville oranges during treatment as they can affect olaparib metabolism through CYP3A4 inhibition, potentially increasing hepatotoxicity risk 1.
The hepatotoxicity mechanism involves CYP3A4/5 metabolism forming hydroxylated metabolites (particularly M12) with high electrophilicity that may explain idiosyncratic liver injury 9.